Doxofylline多索茶碱,69975-86-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Doxofylline

CAS No. : 69975-86-6

MCE 国际站：Doxofylline

产品活性：Doxofylline 是一种口服有效的 PDE IV 抑制剂，也是 A1AR 拮抗剂。Doxofylline 通过抑制线粒体 ROS 的产生，以及改善多种细胞途径 (包括 NLRP3-TXNIP 炎症体的激活) 来减轻上皮细胞的炎症。Doxophylline 可用于哮喘、慢性阻塞性肺病和支气管痉挛的研究。

研究领域：GPCR/G Protein  |  Metabolic Enzyme/Protease  |  Immunology/Inflammation  |  NF-κB

作用靶点：Adenosine Receptor  |  Phosphodiesterase (PDE)  |  Reactive Oxygen Species

In Vitro: Doxofylline (5, 10 µM; 48 h) shows potent protection against LPS-induced epithelial inflammation by reducing PGE 2, NO release, and decreasing mitochondrial ROS generation in 16HBE cells.
Doxofylline (5, 10 µM; 48 h) suppresses LPS-induced expression of NADPH oxidase subunits and TXNIP 16HBE cells.
Doxofylline (5, 10 µM; 48 h) inhibits LPS-induced NLRP3 inflammasome activation and secretion of IL-1b and IL-18, as well as mitigates LPS-mediated SIRT1 reduction.
Doxofylline (0.1-10 µM; 15 min) significantly reduces fMLP-induced leukocyte migration in BM cells (fMLP: Formyl-Methionyl-Leucyl-Phenylalanine).

In Vivo: Doxofylline (0.3, 1 mg/kg; i.p.; single) inhibits LPS-induced inflammation in the lungs of mice.
Doxofylline (0.3 mg/kg; i.p.; pre-treat; single) notably reduces the adhesion of cells to the vascular tissue and surpresses the expression of LPS-induced ICAM-1 in vivo.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  NF-κB Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  FDA-Approved Drug Library  |  Small Molecule Immuno-Oncology Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Antioxidant Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer's Disease Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Mitochondria-Targeted Compound Library  |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Antidepressant Compound Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Mitochondrial Protection Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Acetylcysteine  |  H2DCFDA  |  Deferoxamine mesylate  |  IBMX  |  Elesclomol  |  Quercetin  |  MitoSOX Red  |  L-Ascorbic acid  |  Mito-TEMPO  |  Bucladesine sodium  |  Mitoquinone mesylate  |  L-Glutathione reduced  |  Trolox  |  Zinc Protoporphyrin  |  FX-11  |  Dimethyl fumarate  |  Diphenyleneiodonium chloride  |  Berberine chloride  |  Urolithin A  |  TPEN  |  Sodium dichloroacetate  |  Tempol  |  2-Methoxyestradiol  |  GSK2795039  |  α-Vitamin E  |  Ciprofloxacin  |  Trabectedin  |  Coenzyme Q10  |  Piperlongumine  |  Rolipram

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds